10.1.3 Immunosuppressants

Anakinra (Kineret®)	This High-Cost Drug has been approved for the following indications: - restricted use for adult patients with Secondary Haemophagocytic Lymphohistiocytosis. Approval required from members of the Regional HLH Network. To be prescribed in accordance with the NHSE Clinical Commissioning Policy [210701P] (1924).
For more information and Guidance Click Here	NHSE Clinical Commissioning Policy [210701P] (1924).

Bimekizumab

This High-Cost Drug has been approved for the following indications:

For more information and NICE Guidance Click Here

Bimekizumab for treating axial spondyloarthritis NICE Guidance TA918
ICB commissioned - approval via Blueteq

Bimekizumab for treating active psoriatic arthritis NICE Guidance TA916
ICB commissioned - approval via Blueteq

Filgotinib	This High-Cost Drug has been approved for the following indications: - Moderate to severe rheumatoid arthritis
For more information and NICE Guidance Click Here	Filgotinib for treating moderate to severe rheumatoid arthritis NICE Guidance TA676 ICB commissioned - approval via Blueteq

Guselkumab	This High-Cost Drug has been approved for the following indications: - Active psoriatic arthritis after inadequate response to DMARD
For more information and NICE Guidance Click Here	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs NICE Guidance TA815 ICB commissioned - approval via Blueteq

Risankizumab	This High-Cost Drug has been approved for the following indications: - Treatment of Active Psoriatic arthritis (PsA)
For more information and NICE Guidance Click Here	Risankizumab for treatment of Active Psoriatic arthritis (PsA) NICE Guidance TA803 ICB commissioned - approval via Blueteq

Tofacitinib (Xeljanz®)

This High-Cost Drug has been approved for the following indications: -

Treatment of active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults as per NICE Guidance

For more information and NICE Guidance Click Here

Tofacitinib for treating active ankylosing spondylitis NICE Guidance TA920
ICB commissioned - approval via Blueteq

Upadacitinib (Rivoq®)	This High-Cost Drug has been approved for the following indications: - Treatment of moderate rheumatoid arthritis as per NICE Guidance. Treatment of active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults as per NICE Guidance Treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation that is not controlled well enough with non-steroidal anti-inflammatory drugs in adults as per NICE Guidance.
For more information and NICE Guidance Click Here	Upadacitinib for treating moderate rheumatoid arthritis NICE Guidance TA744 ICB commissioned - approval via Blueteq
	Upadacitinib for treating active ankylosing spondylitis NICE Guidance TA829 ICB commissioned - approval via Blueteq
	Upadacitinib for treating active non-radiographic axial NICE Guidance TA861 ICB commissioned - approval via Blueteq